Elsevier gives full access to its coronavirus information centre content
Elsevier is giving full access to its content on its coronavirus information centre for PubMed Central and other public health databases, such as the...
Free scientific advice for coronavirus medicine or vaccine developers
The European Medicines Agency is offering free scientific advice to coronavirus medicine or vaccine developers. EMA is providing full fee waivers for scientific advice applications from...
Pf Awards 2020 Winners Announced
The Pf Awards 2020 Winners were announced last night, in an event that was live streamed from the Royal Lancaster in London. The 600...
EC approval for AbbVie’s VENCLYXTO® combination regimen
AbbVie has announced that the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with obinutuzumab for the treatment of adult patients with chronic...
Pf Awards 2020 urgent announcement
It is with deepest regret that we have taken the decision to cancel the Pf Awards 2020. The escalating situation with the coronavirus has...
Around 10,000 people could benefit from new migraine drug
NICE has published final draft guidance which recommends fremanezumab (Ajovy, Teva Pharmaceuticals) for preventing chronic migraine meaning around 10,000 people could benefit from the...
Medicines Discovery Catapult nurture next generation drug discovery researchers
Medicines Discovery Catapult (MDC) has welcomed a cohort of MRC-funded PhD students as part of a training, talent and skills agenda to help develop...
Long-term phase III study data on HIV-1 treatment regimen published
ViiV Healthcare has presented 96-week data from its global phase III FLAIR study of the investigational, long-acting, injectable, 2-drug regimen of ViiV Healthcare’s cabotegravir...
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
ViiV Healthcare and UNC-Chapel Hill have announced a five-year renewal of their innovative HIV cure partnership. ViiV Healthcare, the global specialist HIV company majority owned...
Pf Awards 2020 coronavirus update
It is with deepest regret that we have taken the decision to cancel the Pf Awards 2020. Please see our updated statement. With the Pf...
Latest articles
Reputation control: changing perceptions of pharma
Amanda Barrel investigates pharma’s reputation, self-regulation, compliance and how pharma can change perceptions of the work it does. Top 5 Takeaways
1 Only 57% of people...
Medicines and Medical Devices Bill: Getting it right for all
With the Medicines and Medical Devices Bill heading through Parliament, Claudia Rubin asks what is required to get this legislation right? The Government would like...
Popular articles
NICE guidelines on active management of patients with COVID-19
The National Institute for Health and Care Excellence (NICE) has published its first three rapid guidelines on the active management of patients with COVID-19...
FDA emergency authorisation for Roche’s COVID-19 test
Roche has announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its COVID-19 test, the cobas®...
UPDATED: MHRA guidance on coronavirus (COVID-19)
The MHRA is producing guidance on coronavirus (COVID-19) for industry. The Medicines and Healthcare products Regulatory Agency (MHRA) is working closely with Department of Health...
Looking for a breakthrough in Parkinson’s research
Will recent investments and developments offer hope for people living with Parkinson’s? Pf explores the condition and work happening to find a breakthrough in...
Does NICE hold the cards to drug pricing and reimbursement?
The upcoming NICE Methods Review begs the question: at what price does a drug represent value for money to the NHS? Rebecca Lanning discusses...